HUGEL announced on the 3rd that it has begun developing E-type next-generation botulinum toxin.
HUGEL's strategic move to expand its portfolio to various strains, including the A-type botulinum toxin preparation 'Botulex', aims to secure new growth engines.
Since there are no E-type toxin products worldwide, HUGEL expects to be able to establish an unrivaled position in the aesthetic and plastic surgery market if approval and launch are successful.
Type A toxin takes effect gradually 3 to 7 days after administration, and its effectiveness lasts over 6 months. On the other hand, type E is characterized by its effect appearing within 24 hours and lasting for 4 weeks. The new market targets consumers who want quick results.
Numerous studies have proven that E-type botulinum toxin is effective in relieving pain before and after surgery, treating itching, and healing wounds. Thus, it holds significant potential as a versatile treatment option.
HUGEL signed a contract with an American company to commercialize this E-type toxin, introduce strains, and cooperate in development.
"We have begun the development of E-type botulinum toxin, which has not yet been approved globally, with an American toxin research company," said HUGEL Chairman Cha Seok-yong, adding, "We are taking a step towards becoming world-class by developing a new product following Botulex, which is approved and sold in 63 countries."
The link to the Korean version of this article is as below.
▷휴젤, 차세대 보툴리눔 톡신 개발 착수...상용화 성공 기업 無
By_BK Min, KDFN
kdf@kdfnews.com
Source_ⓒHUGEL
